In contrast to the results seen with the full-length SP140L target antigen, only one anti-TIF1γ sample and one systemic sclerosis sample showed immunoreactivity, resulting in an overall specificity of 99%. The gene discussed is TRIM33; the disease is systemic sclerosis.